BA 210

Drug Profile

BA 210

Alternative Names: BA-210; Cethrin; VX-210

Latest Information Update: 11 Apr 2016

Price : $50

At a glance

  • Originator BioAxone Therapeutic
  • Developer BioAxone Biosciences; Vertex Pharmaceuticals
  • Class Neuroprotectants; Recombinant fusion proteins
  • Mechanism of Action Rho GTP-binding protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Spinal cord injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Spinal cord injuries
  • No development reported Age-related macular degeneration; Glaucoma; Optic nerve disorders

Most Recent Events

  • 01 Feb 2016 Phase-II/III clinical trials in Spinal cord injuries (In adolescents, In adults) in USA (Epidural) (NCT02669849)
  • 17 Aug 2015 Phase-II development is ongoing for Spinal cord injuries in USA
  • 23 Sep 2014 No development reported - Preclinical for Optic nerve disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top